"Carl Icahn - one of Wall Street's most renowned and successful investors - is on another mission; this pitbull is sinking his teeth into one of the companies in our portfolio - Enzon Pharmaceuticals (NASDAQ: ENZN)," notes Marc Lichtenfeld.

In Xcelerated Profits Report, the senior analyst and noted healthcare sector expert takes a look at the small cap biotechnology, which is involved in developing products for the treatment of cancer.

"With an infamous reputation for diving into stocks that he perceives as undervalued and shaking up management teams in order to boost shareholder value" , Icahn us one of the best 'business partners' we could have.

"One of the big reasons why we recommended Enzon was because some major institutional investors are clamoring for change at the company. They contend that if Enzon was better at maximizing its true potential, the stock could easily vault from its current undervalued state and generate some real wealth for its shareholders."

"And when it comes to heavy-hitting activists, Carl Icahn sits at the top of the tree. Yes, major firms like Pequot Capital and Iridian Asset Management are also large shareholders, but Icahn is imposing, relentless - and above all, successful."

insert.a.chart.ENZN

While some perceive him as "a troublemaker who doesn't really give a hoot about companies or their employees - just about making money - others see him as "an activist, determined to make businesses better and return value to the very people who are invested in the company."

"And he plans to do just that with Enzon. In fact, just recently Icahn bought an additional 3.1 million ENZN shares, upping his stake to 6.9%. Not only that, he demanded that Enzon executives act to boost shareholder value by spinning off certain assets, or selling the company altogether."

"Icahn believes Enzon is undervalued, and while his demands might have some Enzon executives quaking in their shoes, we're ecstatic that Icahn has decided to take a more active role."

"The two parties are expected to hold further talks, but we expect Enzon's management to continue to meet the demands of the activist investors and for the stock price to appreciate."